GLP1_NEW
Bimasema sc
BIMASEMA_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -0.15 (-10.01 to 9.20) | 0.44 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 93.67 (22.10 to 409) | 0.98 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 35.35 (8.46 to 127) | 0.93 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 22.13 (7.93 to 55.90) | 0.84 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.40 (0.56 to 3.51) | 0.48 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.44 (0.87 to 6.83) | 0.47 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.68 (2.28 to 5.98) | 0.47 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.68 (1.94 to 11.18) | 0.51 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.10 (2.17 to 7.98) | 0.17 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.58 (1.22 to 5.71) | 0.40 |